Free shipping on all orders over $ 500

Tianagliflozin

Cat. No. M31405
Tianagliflozin Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes.

Chemical Information
Molecular Weight 392.88
Formula C21H25ClO5
CAS Number 1461750-27-5
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] John A Spertus, et al. Nat Med. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

[2] Ashish Sarraju, et al. Am Heart J. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

[3] Vlado Perkovic, et al. Lancet Diabetes Endocrinol. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

[4] Bruce Neal, et al. N Engl J Med. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

[5] Rhona Johnston, et al. Health Technol Assess. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Related SGLT Products
JTT-662

JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes.

JP-2266

JP-2266 is a dual SGLT1/2 inhibitor that can be used in studies related to diabetes.

Tofogliflozin

Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

Mizagliflozin

Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

Sergliflozin etabonate

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tianagliflozin supplier, SGLT, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.